Lacerta Therapeutics
AAV Technologies

Unmatched scientific expertise and depth in the development, production, and application of AAV vectors

Targeted Disease Treatments

Besides world-class basic AAV vectorology and clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological disease treatments.

Partnering Opportunities

Our AAV expertise and platforms allow us to offer early access to novel capsid variant identification and robust, scalable AAV vector manufacturing.

Arrow
Arrow
Slider

Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.

lobby-02

We are actively seeking collaborative partnership and out-licensing opportunities providing potential partners with numerous advantages over current AAV vector platforms. Our AAV expertise and platforms allow us to offer early access to novel capsid variant identification and robust, scalable vector manufacturing. By engaging us at an early stage, Lacerta will ensure that the decisions regarding capsid variant derivation and the creation of critical raw production materials are developed effectively in support of the OneBac platform.